Holen Sie sich die Stockscreener-App
132.65
1.40%
1.83
Handel nachbörslich:
133.00
0.35
+0.26%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
ABC's 'Abbott Elementary' teams up with MilliporeSigma to bring mobile science lab to San Jose elementary school students - ABC7 San Francisco
Abbott (ABT) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Sector Update: Health Care Stocks Mixed in Afternoon Trading - MarketScreener
Abbott Laboratories’ TriClip Device: A Promising Investment Backed by Positive TRILUMINATE Trial Results - TipRanks
Abbott TriClip offers substantial improvements in study - MassDevice
Abbott Laboratories Says Trial Results Show Benefits of TriClip System for People With Leaky Heart Valves - MarketScreener
The Zacks Analyst Blog Highlights McDonald's, Abbott Laboratories, O'Reilly Automotive and MIND Technology - TradingView
Abbott's Revolutionary Heart Valve Treatment Cuts Hospitalizations by 27% in Landmark Trial - Stock Titan
Abbott Laboratories’ SWOT analysis: stock outlook amid PFA system approval - Investing.com
Why Abbott Laboratories Stock Leaped by Almost 4% on Thursday - MSN
3 Relatively Safe Stocks to Buy Right Now - The Motley Fool
Top Research Reports for McDonald's, Abbott & O'Reilly Automotive - Yahoo Finance
Abbott snags early CE mark for Volt PFA device - MedTech Dive
$11.66 Bn Lateral Flow Assays Market Insights 2025-2030 with Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, QuidelOrtho, and PerkinElmer DominatingResearchAndMarkets.com - Bluefield Daily Telegraph
Is Abbott Laboratories (ABT) the Best S&P 500 Stock to Buy for Dividend Growth? - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) five-year earnings growth trails the 13% YoY shareholder returns - Yahoo Finance
Why Abbott Laboratories (ABT) Surged On Thursday? - Insider Monkey
Abbott (ABT) Stock Rises on European Approval - GuruFocus
Abbott Laboratories stock outperforms competitors on strong trading day - MSN
Abbott’s Volt enters the PFA fray with CE mark - BioWorld MedTech
Abbott Secures CE Mark for Volt PFA System, Advancing in Competitive PFA Market - Medical Device and Diagnostic industry
Abbott wins CE Mark for Volt PFA system to treat atrial fibrillation, begins EU rollout - MassDevice
Abbott Receives CE Mark for Pulsed Field Ablation System - Diagnostic and Interventional Cardiology
Oppenheimer maintains Abbott Labs target at $134 on CE Mark nod - Investing.com
Abbott accelerates PFA market competition in Europe with early Volt approval - Medical Device Network
Abbott's new AFib device gets early OK from European regulators - Crain's Chicago Business
May 9th Options Now Available For Abbott Laboratories (ABT) - Nasdaq
BTIG maintains Buy on Abbott Labs stock, $140 target - Investing.com India
Abbott gains CE mark approval for Volt PFA system - Cardiovascular Business
Abbott Laboratories Receives CE Mark Certification for Volt Pulsed Field Ablation System - Marketscreener.com
Abbott Laboratories (ABT): Among Dividend Zombies to Invest in - Insider Monkey
Abbott’s Volt Pulsed Field Ablation Nabs EU Approval - MPO-mag
Abbott’s Volt PFA system gains CE Mark for AFib treatment By Investing.com - Investing.com Australia
Abbott’s Volt PFA system gains CE Mark for AFib treatment - Investing.com
Abbott Receives CE Mark For Its Volt(TM) Pulsed Field Ablation System To Treat Patients With Abnormal Heart Rhythms - MarketScreener
Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms - Yahoo Finance
Abbott India Finance Director Jyoti Saraph to resign - Medical Dialogues
Diamond Hill Capital is Crazy About Abbott Laboratories (NYSE:ABT) - Insider Monkey
Behind the Scenes of Abbott Laboratories's Latest Options Trends - Benzinga
Abbott gets FDA nod to begin IVL trial after rivals buy up competition - medtechdive.com
The Zacks Analyst Blog Boston Scientific, Abbott and Medtronic - Yahoo Finance
Abbott Enters Intravascular Lithotripsy Market with FDA-Approved IDE - MD+DI
Abbott (ABT) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Abbott makes IVL move as FDA approves new clinical trial - Cardiovascular Business
Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US - simplywall.st
Abbott gets green light for clinical trials of new heart treatment system - Crain's Chicago Business
Abbott launches intravascular lithotripsy trial aimed at clearing coronary arteries - Fierce Biotech
Abbott Laboratories Gets FDA Approval to Assess Investigational Device in Heart Disease Clinical Trial - Marketscreener.com
TD Cowen maintains $135 target for Abbott Labs stock, reiterates Buy - Investing.com
Abbott is making an IVL play with FDA IDE nod - Mass Device
FDA approves Abbott’s CAD treatment trial - Investing.com India
Abbott Wins FDA IDE Nod for Coronary IVL Trial - MPO-mag
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Lateral Flow Assays Market Analysis Report 2025-2030: Next-generation LFAs, Advancement in LFA Solutions and Reagents, and Rising Acceptance of POC Testing - GlobeNewswire Inc.
Jim Cramer On Abbott Laboratories (ABT): “Abbott Labs Stock Is Back on My Radar” - MSN
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):